Usph.K

The company maintains a conservative capital structure with a debt-to-equity ratio of 0.32, indicating limited leverage relative to shareholder equity. Total liabilities stand at $433.8 million against total equity of $476.4 million, resulting in a net cash position that is negative after subtracting total debt from cash and equivalents of $35.6 million. The current liquidity profile is assessed as medium risk, supported by operating cash flow of $75.1 million which exceeds capital expenditures of $14.1 million, generating positive free cash flow. The market capitalization is $1.2 billion, with a price-to-book ratio of 1.56, suggesting the market values the company slightly above its tangible book value.

Profitability metrics show a return on equity of 8.31% and a return on assets of 3.29%, reflecting moderate efficiency in utilizing assets and equity to generate earnings. The company reported net income of $39.6 million on revenue of $781.0 million, yielding a net margin of approximately 5.1%. Operating income of $86.7 million indicates a healthy operating margin of roughly 11.1%, while gross profit of $149.7 million suggests a gross margin of approximately 19.2%. These returns are evaluated against the backdrop of a price-to-earnings ratio of 30.31, implying investors expect future growth to justify the current valuation multiple.

Revenue concentration and segment details are not explicitly broken down in the available data, but the company operates within the broader healthcare providers and services industry as indicated by sector classification codes. The geographic exposure is not specified in the provided financial snapshot, limiting the ability to assess regional risk factors. The business model relies on the stability of its healthcare-related services, with revenue generation tied to the volume and pricing of its medical or pharmaceutical offerings.

Growth trajectory analysis is constrained by the absence of historical period data in the input. Without five-year annual or eight-quarter quarterly revenue and net income trends, it is not possible to quantify the year-over-year growth rate or identify cyclical patterns. The current revenue base of $781.0 million serves as the baseline for future performance expectations, but historical momentum cannot be verified from the provided data.

Risk assessment highlights medium liquidity risk and low dilution risk. The key flag notes that net cash is negative after subtracting total debt, which may constrain financial flexibility during periods of market stress. The debt-to-equity ratio of 0.32 remains manageable, but the reliance on operating cash flow to service debt obligations is a critical factor. The absence of significant dilution risk suggests that the share count of 15.175 million basic and diluted shares is stable, with no immediate pressure from equity issuances.

Recent events include analyst coverage with a mean price target of $104.00 and a median target of $102.50, indicating a potential upside from the current market price of $79.06. The mean recommendation of 1.71 reflects a bullish sentiment, with three strong-buy and three buy ratings compared to one hold. News observations indicate reconciler activities related to coverage closure, but no specific operational or strategic announcements are detailed in the provided data.